
ALUR Stock Forecast & Price Target
ALUR Analyst Ratings
Bulls say
Allurion Technologies Inc. is poised for significant growth, with projections indicating revenue could reach $51.5 million by 2025, driven by the anticipated market entry and the strong efficacy of its CE-Marked intragastric balloon, which has demonstrated fewer adverse events than competitors. The company has also made notable improvements in its cash burn, positioning itself for financial stability while its AI-powered Virtual Care Suite (VCS) opens up further revenue streams, which enhances its growth prospects. Moreover, successful reimbursement agreements could expand Allurion's addressable market by up to 30% by the end of 2024, underscoring the potential for increased market share as demand for non-drug-based weight loss solutions rises among patients and healthcare providers.
Bears say
Allurion Technologies has reported significant declines in revenue, with a sequential decrease of 55% in 4Q23, leading to total revenue of only $5.4 million, a 70% decline compared to the same quarter in the prior year. The company's management has cited several challenges, including macroeconomic factors, increased competition from GLP-1 medications, and operational issues such as destocking and reduced sales in light of credit risk management. Furthermore, Allurion has consistently experienced operating losses since inception and has been compelled to lower its full-year 2024 revenue guidance while initiating a restructuring plan aimed at cutting operating expenses by 50% in the upcoming year, indicating persistent financial instability.
This aggregate rating is based on analysts' research of Allurion Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ALUR Analyst Forecast & Price Prediction
Start investing in ALUR
Order type
Buy in
Order amount
Est. shares
0 shares